器官移植Issue(6)：420-424,5.DOI:10.3969/j.issn.1674-7445.2015.06.015
非血缘脐血移植治疗高危急性白血病的临床研究
Clinical study on treatment of high-risk acute leukemia with unrelated cord blood transplantation
孙燕玲 1李旭东 1林东军 1方志刚1
作者信息
- 1. 510630 广州，中山大学附属第三医院血液内科 中山大学血液病研究所
- 折叠
摘要
Abstract
Objective To investigate the effect of unrelated cord blood transplantation (UCBT)on the treatment of high-risk childhood and adult acute leukemia.Methods Ten patients with high-risk acute leukemia underwent UCBT.Among the 1 0 patients,3 were children and 7 were adults with the median age of 29 years old (1 1 -41 years old).Six patients underwent one-unit cord blood transplantation and four patients underwent two-unit cord blood transplantation.The myeloablative conditioning regimen without antithymocyte globulin (ATG)was adopted.Cytarabine (Ara-C),fludarabine (Flu)or total body irradiation (TBI)was added on the basis of busulfan (Bu)and cyclophosphamide (Cy).Ciclosporin and mycophenolate mofetil were used to prevent graft-versus-host disease (GVHD).Results The transplantation was successful in 8 (80%) patients.The median implant-time of leukocytes was 1 9 d(1 4-25 d)and that of platelets was 40 d(33-60 d).Three patients developed acute GVHD and no patient developed chronic GVHD.The median follow-up time was 24 months (1 -29 months).Seven patients remained in disease-free survival.Both the 2-year overall survival and disease-free survival rates were 66.7%.Conclusions UCBT is feasible in the treatment of high-risk acute leukemia.UCBT is the preferred option for the high-risk patients without HLA-identical sibling donors,which is characterized by low incidence of GVHD and low recurrence rate.It may make patients with acute leukemia remain long-term survival.关键词
非血缘脐血移植/白血病,急性/急性移植物抗宿主病/白消安/环磷酰胺Key words
Unrelated cord blood transplantation/Leukemia,acute/Graft-versus-host disease/Busulfan/Cyclophosphamide分类
医药卫生引用本文复制引用
孙燕玲,李旭东,林东军,方志刚..非血缘脐血移植治疗高危急性白血病的临床研究[J].器官移植,2015,(6):420-424,5.
